Diabetes: GI Dynamics' EndoBarrier goes directly to pivotal trial in U.S., skips pilot
August 23, 2012 by MassDevice staff
GI Dynamics wins conditional approval for a pivotal clinical trial of its EndoBarrier gastrointestinal lining as treatment for diabetes and obesity, using study data from outside the U.S. to skip pilot trials.
GI Dynamics (ASX:GID) won conditional FDA approval for a U.S. pivotal clinical trial of the EndoBarrier gastrointestinal liner in treatment of diabetes and obesity, skipping the pilot trial process.
- Show full page
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
- Medtech storytelling in the era of comparative effectiveness
Navigation
NEWS
ALung pursues Chinese approval for Hemolung
ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist...
Legal: Patient's lawyer says Intuitive Surgical's training is all about "control"
An attorney for a plaintiff suing robot-assisted surgical systems maker Intuitive Surgical says the...
Can a smartphone help spot a stroke? | MassDevice.com On Call
The American Stroke Assn. and partners release the Spot a Stroke F.A.S.T. smartphone app to help...
Chest docs include Covidien's superDimension lung biopsy device in guidelines
The lung biopsy device acquired by Covidien in its superDimension acquisition is included in new...
Medtronic hits 52-week high on Q4, FY2013 results
Investors sent Medtronic shares to a 52-week high yesterday after the world's largest medical device...
